RANKL

(redirected from RANK ligand)
Also found in: Encyclopedia.

RANKL

(rank'ĕl),
Abbreviation for receptor activator of nuclear factor-κB.

RANKL

, RANK ligand
Thereceptor activator of nuclear factor kappa B ligand, a chemical produced by osteoblasts that causes osteoclasts to proliferate and break down both the cortex and the trabecula of bone.

Excessive activity of this chemical produces pathological bone loss, e.g., in some forms of inflammatory arthritis and in some diseases in which cancers metastasize to bone.

References in periodicals archive ?
XGEVA prevents RANK Ligand from activating its receptor, RANK, on the surface of osteoclasts, thereby decreasing bone destruction.
It is the first and only approved therapy that specifically targets RANK Ligand, an essential regulator of osteoclasts (the cells that break down bone).
Leukaemia Research Fund scientists from Oxford believe they have identified a protein called Rank Ligand, which sabotages the molecules controlling bone regeneration.
But now scientists believe they have identified a rogue protein called Rank ligand, which sabotages the molecules controlling bone regeneration.
Both fundamental research on rank ligand (RANKL) in prostate cancer bone metastasis and other molecular factors involved in the denosumab study were supported at Massachusetts General Hospital with funding from the Prostate Cancer Foundation (PCF).
XGEVA is the first-and-only RANK Ligand inhibitor approved by the FDA for the prevention of SREs in patients with bone metastases from solid tumors.
The original 3-year results of FREEDOM were instrumental in winning marketing approval of the novel RANK ligand inhibitor for the treatment of postmenopausal women with osteoporosis at high risk for fracture.
Osteoprotegerin and rank ligand expression in prostate cancer.
Amgen (NASDAQ: AMGN) today announced findings from the pivotal fracture trial evaluating its RANK Ligand inhibitor, denosumab, in the treatment of postmenopausal osteoporosis.
We currently think that TNF-[alpha] and IL-1 are able to induce osteoclasts and T cells to produce RANK ligand, which binds to the RANK receptor on osteoclast precursor cells and to the RANK receptor of the osteoclast," he said.
Giant cell tumor of bone is rich in RANK Ligand positive cells, which results in giant osteoclasts that destroy the bone locally.
XGEVA is the first-and-only RANK Ligand inhibitor approved by the FDA indicated for the prevention of SREs in patients with bone metastases from solid tumors.